Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC).

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Perceived barriers to and facilitators of physical activity, using the COM-B model for behavioural change, in people with chronic pain: a qualitative evaluation of patient and stakeholder perspectives.

BMC public health·2025

Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022

Same author

Risk factors for chronic pulmonary aspergillosis in post-TB patients.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2021

Same author

Development of probe-based real-time loop-mediated isothermal amplification for detection of Brucella.

Journal of applied microbiology·2018

Same author

Association of opioid prescribing practices with chronic pain and benzodiazepine co-prescription: a primary care data linkage study.

British journal of anaesthesia·2018

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Triple MEL100 therapy in multiple myeloma.

D Berz¹, G A Colvin, E M McCormack

¹Brown University, Providence, Rhode Island, USA. David_Berz@Brown.edu

Transplantation Proceedings

|November 18, 2009

Summary

This study shows that a dose-dense, triple melphalan (MEL100) transplant regimen is well-tolerated in multiple myeloma patients. It offers comparable progression-free survival to standard tandem regimens with manageable side effects.

More Related Videos

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Related Experiment Videos

Last Updated: Jun 18, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Area of Science:

Hematology
Oncology
Stem Cell Transplantation

Background:

Tandem high-dose melphalan with autologous stem cell support is standard for multiple myeloma.
Mucositis and GI issues are common side effects.
Previous triple transplant studies used a less frequent schedule for high-risk patients.

Purpose of the Study:

To investigate a novel, dose-dense triple melphalan (MEL100) regimen.
To evaluate this approach in patients without prohibitive comorbidities.
To assess tolerability and survival outcomes of the every-3-weeks schedule.

Main Methods:

Prospective study of 13 standard or high-risk stage III multiple myeloma patients.
Three cycles of melphalan 100 mg/m(2) on days 1, 20, and 41, with autologous stem cell infusions on days 0, 21, and 42.
Peripheral blood stem cells were collected, divided into three sets, and frozen.

Main Results:

All 13 patients completed all three MEL100 cycles.
54% received treatments on the exact every-3-weeks schedule; some delays occurred.
Median progression-free survival was 854 days; no serious adverse events or Grade III/IV mucositis were recorded.

Conclusions:

The every-3-weeks triple MEL100 regimen is well-tolerated in multiple myeloma.
Progression-free and overall survival appear comparable to standard tandem regimens.
Further studies with larger cohorts are warranted to confirm these findings.